Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Clinical trial NCT02609776 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02609776
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-24
- Primary completion
- 2026-12-31
- Enrollment
- 751
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.